Literature DB >> 19187767

Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex.

Yingxin L Zhang1, Mala L Radhakrishnan, Xiaohui Lu, Alec W Gross, Bruce Tidor, Harvey F Lodish.   

Abstract

Via sites 1 and 2, erythropoietin binds asymmetrically to two identical receptor monomers, although it is unclear how asymmetry affects receptor activation and signaling. Here we report the design and validation of two mutant erythropoietin receptors that probe the role of individual members of the receptor dimer by selectively binding either site 1 or site 2 on erythropoietin. Ba/F3 cells expressing either mutant receptor do not respond to erythropoietin, but cells co-expressing both receptors respond to erythropoietin by proliferation and activation of the JAK2-Stat5 pathway. A truncated receptor with only one cytosolic tyrosine (Y343) is sufficient for signaling in response to erythropoietin, regardless of the monomer on which it is located. Similarly, only one receptor in the dimer needs a juxtamembrane hydrophobic L253 or W258 residue, essential for JAK2 activation. We conclude that despite asymmetry in the ligand-receptor interaction, both sides are competent for signaling, and appear to signal equally.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187767      PMCID: PMC2706114          DOI: 10.1016/j.molcel.2008.11.026

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  24 in total

1.  Rational design of potent antagonists to the human growth hormone receptor.

Authors:  G Fuh; B C Cunningham; R Fukunaga; S Nagata; D V Goeddel; J A Wells
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

Review 2.  Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?

Authors:  Stuart J Frank
Journal:  Endocrinology       Date:  2002-01       Impact factor: 4.736

3.  Efficiency of signalling through cytokine receptors depends critically on receptor orientation.

Authors:  R S Syed; S W Reid; C Li; J C Cheetham; K H Aoki; B Liu; H Zhan; T D Osslund; A J Chirino; J Zhang; J Finer-Moore; S Elliott; K Sitney; B A Katz; D J Matthews; J J Wendoloski; J Egrie; R M Stroud
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

4.  Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation.

Authors:  R Lammers; E Van Obberghen; R Ballotti; J Schlessinger; A Ullrich
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

5.  Mapping of the active site of recombinant human erythropoietin.

Authors:  S Elliott; T Lorenzini; D Chang; J Barzilay; E Delorme
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

6.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.

Authors:  S N Constantinescu; L J Huang; H Nam; H F Lodish
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

7.  Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.

Authors:  Y Miura; O Miura; J N Ihle; N Aoki
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

8.  Attenuated signaling by a phosphotyrosine-null Epo receptor form in primary erythroid progenitor cells.

Authors:  Ke Li; Madhu P Menon; Vinit G Karur; Shailaja Hegde; Don M Wojchowski
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

9.  Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis.

Authors:  O Miura; A D'Andrea; D Kabat; J N Ihle
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

10.  Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation.

Authors:  J E Damen; H Wakao; A Miyajima; J Krosl; R K Humphries; R L Cutler; G Krystal
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  15 in total

1.  Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries.

Authors:  Hongkai Zhang; Ian A Wilson; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

2.  Sortase-catalyzed transformations that improve the properties of cytokines.

Authors:  Maximilian W Popp; Stephanie K Dougan; Tzu-Ying Chuang; Eric Spooner; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-04       Impact factor: 11.205

3.  IFN-γ directly inhibits the activity of erythropoietin in human erythroid progenitors.

Authors:  Daisuke Araki; Luigi J Alvarado; Heather D Huntsman; Richard H Smith; Andre Larochelle
Journal:  Blood Cells Mol Dis       Date:  2020-08-21       Impact factor: 3.039

4.  Immunosuppressive effects of erythropoietin on human alloreactive T cells.

Authors:  Paolo Cravedi; Joaquin Manrique; Katherine E Hanlon; Jessica Reid-Adam; Joshua Brody; Praeophayom Prathuangsuk; Anita Mehrotra; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

Review 5.  The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.

Authors:  Stephanie S Watowich
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

6.  Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor.

Authors:  Nicholas J Pekas; Jason L Petersen; Monica Sathyanesan; Samuel S Newton
Journal:  Drug Des Devel Ther       Date:  2020-12-04       Impact factor: 4.162

Review 7.  Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Authors:  Nicole Rainville; Edward Jachimowicz; Don M Wojchowski
Journal:  Expert Opin Ther Targets       Date:  2015-09-30       Impact factor: 6.902

8.  Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production.

Authors:  Ruifeng Teng; Oksana Gavrilova; Norio Suzuki; Tatyana Chanturiya; Daniel Schimel; Lynne Hugendubler; Selin Mammen; Dena R Yver; Samuel W Cushman; Elisabetta Mueller; Masayuki Yamamoto; Lewis L Hsu; Constance Tom Noguchi
Journal:  Nat Commun       Date:  2011-11-01       Impact factor: 14.919

9.  Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways.

Authors:  Manfred Nairz; Andrea Schroll; Alexander R Moschen; Thomas Sonnweber; Milan Theurl; Igor Theurl; Nicole Taub; Christina Jamnig; Daniela Neurauter; Lukas A Huber; Herbert Tilg; Patrizia L Moser; Günter Weiss
Journal:  Immunity       Date:  2011-01-20       Impact factor: 31.745

Review 10.  Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration.

Authors:  Hal E Broxmeyer
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.